Hikma Pharmaceuticals plc’s pain could be GlaxoSmithKline plc’s gain

Could ongoing approval issues at Hikma Pharmaceuticals plc (LON: HIK) and rivals help GlaxoSmithKline plc (LON:GSK) preserve its dividend?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Hikma Pharmaceuticals (LSE: HIK) today downgraded its 2017 forecast for the third time this year and now expects revenues of around $2bn, down from previous guidance of $2.1bn-$2.2bn. The announcement of a licensing agreement with Takeda couldn’t prevent the shares from plummeting 9% in early trading, knocking the share price down to nearly half what it was just 12 months ago. 

The company was hit by the devaluation of the Egyptian pound and an increasingly tough environment in the US where “competition is increasing and pricing pressure is intensifying,” according to CEO Said Darwazah.

First-half revenue rose 1%, while operating profit fell 7% after a strong performance in Generics was offset by a weaker showing from Branded Generics. Strong operating cash flow helped the company reduce net debt from $697m to $633m, a perfectly healthy level considering the defensive nature of pharma companies.

Should you invest £1,000 in Hikma right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Hikma made the list?

See the 6 stocks

Investors will surely be disappointed, but some cautiously optimistic comments regarding Hikma’s Advair generic will go some way to soothing long-term fears. Sales of Advair, GlaxoSmithKline’s (LSE: GSK) premier blockbuster drug, have held up better than expected since its patent expired back in 2016, because the Diskus delivery system it employs has been a tough one to crack for both Hikma and rivals Mylan and Novartis alike.

Hikma said it has managed to “clarify and resolve” a number of the FDA’s questions regarding the key drug and reiterated there were “no material issues” concerning eventual approval. A more detailed update has been promised, but given the deterioration in the company’s outlook, investors might not relax until more context has been given.

These delays are certainly to the benefit of Glaxo. Its massive 5.3% yield is barely covered by cash-flow and the extended no-competition period for Advair grants some much-needed breathing space so it can squeeze more out of its other businesses.

Right direction

I firmly believe that GSK is moving in the right direction and that a combination of margin expansion and slow-but-steady sales growth will eventually better cover the dividend. If this happens, it would not be surprising to see the shares re-rate to a more normal yield of around 4.5%, indicating a near 20% upside if the market gets comfortable with the payout.

The company’s free cash flow jumped from £0.1bn in the first half of this year to £0.4bn, but if it is to achieve its target “to build free cash flow cover of the annual dividend to a target range of 1.25-1.50x,” it must continue its run of form.

The rate of inevitable decline in Advair sales will be key for GSK over the next few years, as will performance in its HIV division which has really picked up the slack for the company of late. The firm did warn of “the impact of generic competition to Epzicom/Kivexa,” so investors would do well to keep a close eye of the performance from the HIV treatments in future updates.

I find both companies attractive propositions at current prices. Hikma has had a terrible year, but its strong presence in North Africa and the Middle East should continue to drive growth as healthcare spend increases. Similarly, Glaxo might run into some short-term issues covering the dividend, but its pipeline looks bright and I’m cheered by new CEO Emma Wamlsley’s strategic plan, specifically regarding a refocusing of capital allocation in the pharma business.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zach Coffell owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

This world-class FTSE 100 company’s expecting up to 10% growth in 2025

This is one of the most profitable companies in the FTSE 100 index. And right now, it’s firing on all…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

£10k invested in Phoenix shares 10 years ago would have generated passive income of…  

Shares in this FTSE 100 insurance giant have done poorly over the last decade. Harvey Jones wonders if super-sized passive…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

This brilliant FTSE income share just paid me £458 for doing absolutely nothing – I love it!

Harvey Jones is sending some love to high-yielding FTSE 100 dividend income share M&G today in return for it sending…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

Should I buy Palantir (PLTR) stock for my ISA in 2025?

Palantir stock's flying in 2025, having risen almost 60% already. Should Edward Sheldon take the plunge and buy the growth…

Read more »

Workers at Whiting refinery, US
Investing Articles

Drowning in debt amid falling oil prices, can the BP share price recover?

By far the worst-performing of the oil majors, Andrew Mackie assesses just what it will take to kick life back…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

As Cash ISA changes approach, is now the time to buy UK shares for long-term wealth?

Changes to the Individual Savings Account (ISA) could present an unexpected opportunity to try to get richer with UK shares.

Read more »

Emma Raducanu for Vodafone billboard animation at Piccadilly Circus, London
Investing Articles

What’s the point of investing in Vodafone, the FTSE 100’s 31st most valuable stock?

Our writer’s becoming increasingly frustrated with the share price performance of this FTSE 100 stock that was once the most…

Read more »

Lady taking a carton of Ben & Jerry's ice cream from a supermarket's freezer
Investing Articles

‘Britain’s Warren Buffett’ isn’t a fan of UK shares (except this one)

Terry Smith, founder and CEO of Fundsmith, has been described as a 'British Warren Buffett'. But he’s not that keen…

Read more »